AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza…
Drug Manufacturers - General
GB, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -34.34 | 52.23 | 79.56 | |
| Graham Fair Price | 47.35 | 13.83 | 9.39 | |
| PEG | -89.12 | 0.19 | -1.75 | |
| Price/Book | 4.38 | 5.56 | 5.33 | |
| Price/Cash Flow | 47.01 | 213.90 | 145.50 | |
| Prices/Earnings | -56.01 | 23.90 | 54.34 | |
| Price/Sales | -5.31 | 16.43 | 17.35 | |
| Price/FCF | 47.01 | 213.90 | 145.50 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -6.92 | 0.75 | 0.81 | |
| Operating Margin | 149.38 | 0.26 | 0.10 | |
| ROA | 124.37 | 0.02 | < 0.005 | |
| ROE | 0.02 | 0.06 | 137.27 | |
| ROIC | 0.02 | 0.04 | 82.93 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.21 | < 0.005 | 12768.42 | |
| Dividends QOQ | -1.00 | 1515.50 | 151665.27 | |
| EBIT QOQ | -0.37 | 1.63 | 342.27 | |
| EPS QOQ | -0.31 | 1.26 | 304.38 | |
| FCF QOQ | -0.36 | -0.32 | 10.49 | |
| Revenue QOQ | 0.05 | 0.05 | 17.67 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 211.51 | 152.83 | -27.74 | |
| Days Sales Outstanding (DSO) | 101.44 | 86.78 | -14.45 | |
| Inventory Turnover | 0.43 | 0.59 | 38.40 | |
| Debt/Capitalization | 0.42 | 0.47 | 11.95 | |
| Quick Ratio | 0.64 | 0.70 | 10.22 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 12.63 | 12.09 | -4.34 | |
| Cash | 1.89 | 2.59 | 36.88 | |
| Capex | -0.31 | -0.52 | -69.66 | |
| Free Cash Flow | 0.46 | 0.31 | -32.08 | |
| Revenue | 3.88 | 4.09 | 5.45 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad